IP Library Granted Patent US 7,935,526
Granted Patent B2
US 7,935,526 · App. 10/595,858 · Granted May 3, 2011

hERG channel-expressing cell

Assignee: Eisai R & D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,526
App. No.
10/595,858
Granted
May 3, 2011
Kind
B2
Abstract

It is an object of the present invention to establish a method of establishing a cell with a remarkably high hERG channel expression level for use in predicting adverse effects based on hERG channel inhibition in research and development of drugs, and to thereby establish a highly sensitive and high throughput evaluation method. By inserting a hERG gene into a retrovirus vector plasmid or lentivirus vector plasmid to thereby prepare a virus vector, concentrating the vector by ultracentrifugation if necessary, transferring the hERG gene into cells and expressing hERG channels therein, it has become possible to secure an expression level effective in measurements using a fully automated high throughput patch clamp system or dyes.

Claims (17)

1. A hERG channel-expressing cell population comprising cells capable of expressing a channel of which the hERG current as determined by patch clamping with a fully automated high throughput patch clamp system is 0.6 nA or more,

wherein the proportion of said cells is 40% or more relative to the total number of hERG gene-transferred cells within said population, and

wherein the hERG gene has been transferred with a retrovirus vector.

2. The cell population according to claim 1 , wherein the average value of the hERG current in the total cell population is 0.3 nA or more.

3. A hERG channel-expressing cell population of claim 1 , wherein the hERG current as determined by patch clamping with a fully automated high throughput patch clamp system is 1.0 nA or more.

4. A method of preparing the cell population according to claim 1 , the method comprising expressing hERG channels via a retrovirus vector.

5. The method according to claim 4 , the method further comprising the step of concentrating the virus vector by ultracentrifugation.

6. A method of measuring hERG current inhibitory activity, the method comprising using the cell population of claim 1 .

7. The method according to claim 6 , the method further comprising using a fully automated high throughput patch clamp system.

8. A method of measuring hERG current inhibitory activity, the method comprising using a cell population or a cell prepared by the method according to claim 4 .

9. The method according to claim 8 , the method further comprising using a fully automated high throughput patch clamp system.

10. A method of screening a compound or a salt thereof for its hERG current altering effect, the method comprising using a cell population according to claim 1 .

11. The method according to claim 10 , the method further comprising using a fully automated high throughput patch clamp system.

12. A method of screening a compound or a salt thereof for its hERG current altering effect, the method comprising using a cell population or a cell prepared by the method according to claim 4 .

13. The method according to claim 12 , the method further comprising using a fully automated high throughput patch clamp system.

14. A method of measuring hERG current inhibitory activity, the method comprising using the cell population according to claim 3 .

15. A method of screening a compound or a salt thereof for its hERG current altering effect, the method comprising using the cell population according to claim 3 .

Assignments (2)
DIVISION OF COMPANY Recorded Dec 27, 2006
From: EISAI CO., LTD.
To: EISAI R & D MANAGEMENT CO., LTD.
Reel/Frame 018680/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2006
From: YOSHINAGA, TAKASHI; ARAI, TORU
To: EISAI CO., LTD.
Reel/Frame 017909/0951 →
Priority Claims (1)
JP 2003-387255 · Nov 17, 2003 · national
Continuity (1)
Related Publication 20060292546A1 · Dec 28, 2006